Dexmedetomidine shortens agitation, not delirium, in non-intubated ICU patients
The 4D trial provides the first randomized placebo-controlled evidence that dexmedetomidine improves a composite of agitation, delirium, and intubation control in non-intubated hyperactive delirious ICU adults, though the driver is a roughly one-hour reduction in agitation duration.
📅 Journal publication: Dec 2025(online Oct 29, 2025)·Last updated: Sep 26, 2026
Dexmedetomidine shows promise for delirium in non-intubated ICU patients.
Managing hyperactive delirium in non-intubated ICU patients is challenging, and current options are limited by side effects. Dexmedetomidine significantly reduced delirium symptoms compared to placebo, with fewer adverse effects reported. While promising, further studies are needed to confirm these findings across diverse patient groups and settings. Dexmedetomidine may be effective and safer for hyperactive delirium in non-intubated ICU patients.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Godet T, Louis C, Rieu B, De Jong A, Couhault P, Pradel G, Tête H, Bourguignon N, Borao L, Jabaudon M, Futier E, Jaber S, Pereira B, Chanques G, Constantin JM, 4D study group
Citation:Godet T, Louis C, Rieu B, et al. Dexmedetomidine for treatment of hyperactive delirium in non-intubated ICU patients: the 4D randomized clinical trial. Intensive care medicine. 2025;51(12):2305-2317. doi:10.1007/s00134-025-08135-1